EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access

Deprescribing Antidepressants in Children and Adolescents: A Systematic Review of Discontinuation Approaches, Cross-Titration, and Withdrawal Symptoms

Absetzen von Antidepressiva bei Kindern und Jugendlichen: systematische Übersichtsarbeit zu Absetzstrategien, Cross-Titration und Absetzsymptomen

Julia N Stimpfl iD, John T Walkup, Adelaide S Robb, Alexandra E Alford, Stephen M Stahl, James T McCracken, Stephani L Stancil iD, Laura B Ramsey iD, Graham J Emslie, Jeffrey R Strawn iD

Journal of Child and Adolescent Psychopharmacology · 2025-02 · 35 (1) · 3-22

DOI: 10.1089/cap.2024.0099 ↗

Auf einen Blick

Die Übersichtsarbeit beschreibt Daten zum Absetzen von Antidepressiva bei Kindern und Jugendlichen. Absetzsymptome und die Umstellung zwischen Präparaten hängen laut Autor:innen mit pharmakokinetischen Eigenschaften zusammen.

Fragestellung

Welche Daten gibt es zum Absetzen von Antidepressiva bei Kindern und Jugendlichen, zu Absetzsymptomen und zu Strategien für Cross-Titration?

Methode

Systematische Übersichtsarbeit; Suche in PubMed und ClinicalTrials.gov bis 1. Juni 2024; Zusammenfassung randomisierter kontrollierter Studien und pharmakokinetischer Daten.

Ergebnisse

13 randomisierte, doppelblinde, placebokontrollierte Studien mit 3026 Patient:innen; zusätzlich 14 weitere Datensätze aus 19 Records. Studien zu SSRIs (K = 10), SNRIs (K = 4) und TCAs (K = 1), Dauer 4 bis 35 Wochen.

Schlussfolgerung der Autor:innen

Empirisch gestützte Daten zum Absetzen von Antidepressiva bei pädiatrischen Patient:innen nehmen zu und sollten Entscheidungen zu wann und wie das Absetzen erfolgt informieren.

Kernaussagen

  • 13 randomisierte, doppelblinde, placebokontrollierte Studien
  • Absetzsymptome variieren mit den pharmakokinetischen Eigenschaften
  • Daten zu Verlauf von Rückfall und Withdrawal sollen das Absetzen informieren

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Child and Adolescent Psychopharmacology, online erschienen am 31.01.2025. Verfasst von Julia N Stimpfl und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry & Behavioral Neuroscience, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Substance Withdrawal Syndrome, Deprescriptions, Antidepressive Agents. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Antidepressant medications, including selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), are commonly used to treat depressive, anxiety, and obsessive-compulsive disorders in youth. Yet, data on discontinuing these medications, withdrawal symptoms, and strategies to switch between them are limited.

Methods

We searched PubMed and ClinicalTrials.gov through June 1, 2024, to identify randomized controlled trials assessing antidepressant discontinuation in youth. We summarized pediatric pharmacokinetic data to inform tapering and cross-titration strategies for antidepressants and synthesized these data with reports of antidepressant withdrawal.

Results

Our search identified 528 published articles, of which 28 were included. In addition, 19 records were obtained through other methods, with 14 included. The corpus of records included 13 randomized, double-blind, placebo-controlled trials (3026 patients), including SSRIs (K = 10), SNRIs (K = 4), and TCAs (K = 1), ranging from 4 to 35 weeks. Deprescribing antidepressants requires considering clinical status, treatment response, and, in cross-titration cases, the pharmacokinetics and pharmacodynamics of both medications. Antidepressant withdrawal symptoms are related to the pharmacokinetics of the medication, which vary across antidepressants and may include irritability, palpitations, anxiety, nausea, sweating, headaches, insomnia, paresthesia, and dizziness. These symptoms putatively involve changes in serotonin transporter expression and receptor sensitivity, impacting the serotonin, dopamine, and norepinephrine pathways.

Conclusions

Although approaches to deprescribing antidepressants in pediatric patients are frequently empirically guided, accumulating data related to the course of relapse and withdrawal symptoms, as well as the pharmacokinetic and pharmacodynamic properties of medications, should inform these approaches. Recommendations within this review support data-informed discussions of deprescribing—including when and how—that are critically important in the clinician–family–patient relationship.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Substance Withdrawal SyndromeDeprescriptionsAntidepressive AgentsHumansChildAdolescentRandomized Controlled Trials as TopicSelective Serotonin Reuptake InhibitorsSerotonin and Noradrenaline Reuptake Inhibitors

Stichwörter der Autor:innen

antidepressantanxietydepressionselective serotonin reuptake inhibitor (SSRI)serotonin-norepinephrine reuptake inhibitor (SNRI)

Substanzen

Antidepressive AgentsSelective Serotonin Reuptake InhibitorsSerotonin and Noradrenaline Reuptake Inhibitors

Autor:innen und Institutionen

  • Department of Psychiatry & Behavioral Neuroscience, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
  • Pritzker Department of Psychiatry and Behavioral Health, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
  • Department of Psychiatry and Behavioral Sciences, Children's National Hospital, George Washington University School of Medicine, Washington DC, USA.
  • Department of Psychiatry, University of California, San Diego, California, USA.
  • Department of Psychiatry, University of California, San Francisco, California, USA.
  • Department of Pediatrics, Schools of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.

ORCID-Profile: Julia N Stimpfl, Stephani L Stancil, Laura B Ramsey, Jeffrey R Strawn

Förderung

  • NIMH NIH HHS

Zitieren

APA

Stimpfl, J. N., Walkup, J. T., Robb, A. S., Alford, A. E., Stahl, S. M., McCracken, J. T., Stancil, S. L., Ramsey, L. B., Emslie, G. J., & Strawn, J. R. (2025). Deprescribing Antidepressants in Children and Adolescents: A Systematic Review of Discontinuation Approaches, Cross-Titration, and Withdrawal Symptoms. Journal of Child and Adolescent Psychopharmacology, 35(1), 3-22. https://doi.org/10.1089/cap.2024.0099

Vancouver

Stimpfl JN, Walkup JT, Robb AS, Alford AE, Stahl SM, McCracken JT, et al. Deprescribing Antidepressants in Children and Adolescents: A Systematic Review of Discontinuation Approaches, Cross-Titration, and Withdrawal Symptoms. Journal of Child and Adolescent Psychopharmacology. 2025;35(1):3-22. doi:10.1089/cap.2024.0099

BibTeX
@article{Stimpfl2025,
  author = {Stimpfl, Julia N and Walkup, John T and Robb, Adelaide S and Alford, Alexandra E and Stahl, Stephen M and McCracken, James T and Stancil, Stephani L and Ramsey, Laura B and Emslie, Graham J and Strawn, Jeffrey R},
  title = {Deprescribing Antidepressants in Children and Adolescents: A Systematic Review of Discontinuation Approaches, Cross-Titration, and Withdrawal Symptoms},
  journal = {Journal of Child and Adolescent Psychopharmacology},
  year = {2025},
  volume = {35},
  number = {1},
  pages = {3--22},
  doi = {10.1089/cap.2024.0099}
}
Kostenlos starten →